Assessment of Quality of Life After Acute Mesenteric Ischemia (EQVIMA-1)

December 11, 2025 updated by: University Hospital, Strasbourg, France
Acute mesenteric ischemia is a severe abdominal emergency associated with a poor prognosis. While numerous studies have been conducted on the incidence, outcomes, and risk factors of mesenteric ischemia, very few focus on the quality of life of patients.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service d'Anesthésie - CHU de Strasbourg - France
        • Sub-Investigator:
          • Olivier COLLANGE, MD
        • Sub-Investigator:
          • Julien GODET, Statistician
        • Contact:
        • Principal Investigator:
          • Astrid WELVAERT, MD
        • Sub-Investigator:
          • Quentin TOURTET, MD
        • Sub-Investigator:
          • Guillaume PHILOUZE, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patient (≥ 18 years) treated for mesenteric ischemia in the Strasbourg University Hospitals

Description

Inclusion Criteria:

  • Adult patient (≥ 18 years)
  • Treated for mesenteric ischemia between 2010 and 2022 in the intensive care, cardiovascular, and digestive and vascular surgery departments of the Strasbourg University Hospitals

Exclusion Criteria:

  • Chronic mesenteric ischemia or other non-ischemic intestinal vascular pathologies such as mechanical causes.
  • Colonic ischemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Score of GIQLI (Gastrointestinal Quality of Life Index)
Time Frame: Up to 12 months

The GIQLI quality of life score consists of 36 items:

the higher the score, the better the quality of life.
Up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2024

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

April 1, 2026

Study Registration Dates

First Submitted

December 11, 2025

First Submitted That Met QC Criteria

December 11, 2025

First Posted (Actual)

December 24, 2025

Study Record Updates

Last Update Posted (Actual)

December 24, 2025

Last Update Submitted That Met QC Criteria

December 11, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 9481

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Mesenteric Ischemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe